Analysis of Domestic Medical Insurance Coverage of Avonib

Ivosidenib (Ivosidenib), a drug specifically designed to treat acute myeloid leukemia carrying isocitrate dehydrogenase1 (IDH1) mutation (AML) Targeted therapy drugs designed for patients effectively block the abnormal metabolic pathways of cancer cells by inhibiting the activity of IDH1 enzyme, thereby curbing the growth of tumors. This unique targeting mechanism allows ivonib to show significant efficacy in the treatment of AML patients, especially those who are insensitive to or have developed resistance to traditional chemotherapy.

Although ivonib has been launched in China, bringing new treatment hope to domestic patients, this drug has not yet been included in the scope of national medical insurance reimbursement. This means that patients need to purchase it at their own expense, which undoubtedly increases the financial burden of treatment. According to market knowledge, the domestic selling price of Avonib is about RMB 30,000 to RMB 40,000 per box. The high price requires patients to carefully consider economic factors when choosing treatment options, and it is recommended to consult the local hospital pharmacy to obtain accurate price information before purchasing drugs.

Because ivonib is not included in medical insurance reimbursement, many patients face huge financial pressure. In this case, foreign generic drugs have become a more economical alternative. In particular, generic drugs produced in Laos have attracted market attention due to their lower prices and relatively stable supply. The price of generic drugs in Laos is about 6,000 to 7,000 yuan, which is much cheaper than domestic original drugs. Although the price difference is significant, Lao generic drugs are basically the same as the original drugs in terms of drug ingredients and efficacy, providing patients with an affordable treatment option.

In summary, ivonib is an important drug for the treatment of patients with IDH1 mutationsAML. Although it has been marketed in China, its high price and the fact that it is not covered by medical insurance put patients under certain financial pressure during the treatment process. For patients with limited financial conditions, considering foreign generic drugs may be a more feasible option. When choosing a treatment plan, it is recommended that patients fully communicate with their doctors and choose the most suitable treatment path based on their own financial situation and condition.